📋 What This Document Is 📰

This filing is a Form 6-K, which is a public report used by international companies to announce material, significant events to U.S. investors. 📈 Essentially, it serves as a major corporate announcement regarding the strategic direction, leadership changes, and commercial plans for the product "unbuzzd."

👉 Why it matters: This press release is a major operational milestone, detailing how the company plans to move its scientifically-backed beverage from a supplement niche into a large, national commercial product.

🧑‍🔬 The Companies Involved 🧬

The filing discusses two distinct entities: Quantum BioPharma Ltd. and Unbuzzd Wellness Inc. Both are related but have different focuses. 🔬

• Quantum BioPharma Ltd. (QNTM): This company is a biopharmaceutical firm focused on developing innovative assets and biotech solutions for serious medical conditions, such as neurodegenerative and metabolic disorders, and alcohol misuse disorders.
  • Key Asset: It owns its subsidiary, Lucid Psycheceuticals Inc., which is developing a patented compound called Lucid-MS, aimed at preventing and reversing myelin degradation (the mechanism underlying multiple sclerosis) in preclinical models.
• Unbuzzd Wellness Inc. (UWI): This is the spin-off company that owns the popular product, unbuzzd™. It is a pioneer in the wellness and recovery supplement space.
  • The Product: unbuzzd™ is a proprietary blend of vitamins, minerals, and herbs in ready-to-mix powder stick formats. It claims to help the body process alcohol faster, restore mental clarity, and improve cognition.

🧑‍💼 Leadership and Strategy Changes 🧭

The most immediate news is a significant leadership shakeup within Unbuzzd Wellness Inc. (UWI), aimed at accelerating the product's commercial success. 🚀

• New CEO: Richard Buzbuzian has been appointed as the new Chief Executive Officer of Unbuzzd Wellness Inc. He brings "vision and capital markets acumen" necessary for scaling the company.
• Reporting Structure: Dr. Eric Hoskins, Director, highlighted the timing of this appointment, stating, "Buzbuzian's vision, business acumen, and understanding of capital markets comes to unbuzzd as we pursue market expansion across North America and abroad in retail and online settings."
• Product Consultant: John Duffy is welcomed into a new role as Product Consultant. While he previously served as CEO, his new role focuses on assisting with product development and national distribution.

🏥 Clinical Validation and Product Edge ✨

The core strength of the product, unbuzzd, is its scientific backing, which the company emphasizes is a key differentiator in the market. 🧪

• Proof of Efficacy: Unlike many competitors, unbuzzd is highlighted as the only product backed by a peer-reviewed clinical study proving its ability to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms.
• The Study: This crucial study was published in the World Journal of Pharmaceutical and Medical Research in 2026 (Volume 12, Issue 3, pages 446-467).
  • 👉 Why it matters: Clinical validation is paramount in the supplement industry, as it builds both consumer trust and investor confidence, allowing the company to claim "category-defining" leadership.
• Formulation: The product uses a proprietary blend of vitamins, minerals, and herbs developed by a world-class R&D team, combining metabolic science with simple, clean label ingredients.

📊 Market Opportunity and Growth Potential 📈

The company is positioning itself within a rapidly expanding and appealing sector: the functional beverage market. 💧

• Market Size: The functional beverage market is projected to reach a massive $198 billion in 2026. It is also expected to grow at a 10.79% Compound Annual Growth Rate (CAGR).
  • 👉 Why it matters: The sheer size of the market provides a massive runway for growth and indicates that demand for beneficial, "better-for-you" products is strong and sustained.
• Consumer Trends: The underlying consumer shift is highly favorable:
  • 70% of Americans are actively looking for health benefits from their beverage choices.
  • 72% of Gen Z consumers are trying new beverages monthly.
  • 👉 Why it matters: This confluence of health consciousness and youth experimentation provides a ready-made, receptive audience for unbuzzd's proposition.

🛒 Commercialization Strategy and Distribution 🌍

The plan for bringing unbuzzd to the masses involves an aggressive, multi-pronged national rollout. 🛣️

• Geographic Focus: The initial strategic market expansion will focus on South Florida and Texas, two regions identified as having "America's most dynamic consumer markets."
• Sales Channels: The company’s growth strategy targets a multi-channel distribution approach, aiming to reach consumers through diverse points of sale, including:
  • Pharmacies
  • Liquor stores
  • Supermarkets
  • Mass merchandisers
  • Convenience stores
  • College stores
• Scaling: The company is building a "scalable platform" capable of supporting both traditional retail partnerships and e-commerce sales across North America and internationally.

💹 Corporate Financial Positioning and Ownership 💰

This section outlines the legal and financial relationship between Quantum BioPharma and Unbuzzd Wellness, which is critical for understanding future revenue streams. 📜

• QNTM's Stake in UWI: Quantum BioPharma retains ownership of 19.84% of Unbuzzd Wellness Inc. as of December 31, 2025.
• Royalty Payments: The agreement dictates two royalty payment stages:
  • Initially, UWI pays Quantum BioPharma 7% of sales from unbuzzd™.
  • This royalty percentage is scheduled to drop to 3% in perpetuity once total payments reach $250 million.
  • 👉 Why it matters: The initial 7% royalty provides a strong, immediate revenue source for Quantum BioPharma, linking its financial interest directly to the product's commercial success.
• QNTM's IP Retention: Quantum BioPharma retains 100% of the rights to develop any similar product or alternative formulation specifically for pharmaceutical and medical uses, ensuring its core R&D interest is protected.

🔮 Forward-Looking Goals and Guidance 🔭

The company provided several clear, forward-looking goals regarding its future market execution. These statements are based on assumptions about market stability and execution capability. 📅

• Strategic Development: Buzbuzian stated, "We are building a sustainable, scalable platform capable of delivering ready-to-drink formats and expanding our proprietary product line to meet evolving consumer demand for functional, better-for-you beverages."
• Market Opportunity: The CEO reiterated the "total addressable market for unbuzzd is substantial," positioning the company to capitalize on the opportunity created by combining metabolic science with a clean label.
• Listing Intent: The company intends to seek a listing of its securities on a stock exchange.

⚠️ Risks and Uncertainty Disclosure 🛑

As is required by regulatory filings, the company provides a detailed warning about the risks inherent in its plans. Investors must read these to understand potential roadblocks. 🚧

• Execution Risk: The primary risk cited is the inability to successfully execute the commercialization and distribution plans or to enter new markets as anticipated.
• Operational Risks: Risks exist related to manufacturing, supply chain logistics, and distribution arrangements.
• Market & Regulatory Risks: The company notes risks related to market competition, potential changes in advertising or labeling regulations, and the general difficulty in obtaining a listing on a stock exchange.
  • 👉 Why it matters: These warnings remind readers that projected growth and financial success depend on many complex factors outside the company's direct control.

📞 Contact Information and Next Steps 📧

If investors or journalists wish to follow up on this announcement, the necessary contacts are provided. 🌐

• Quantum BioPharma Ltd. Contact:
  • Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
  • Email: [email protected]
  • Phone: (416) 854-8884
• Investor Relations:
  • Email: [email protected], [email protected]
  • Website: www.quantumbiopharma.com

🧠 The Analogy 🍦

Think of the functional beverage market like a giant, highly desirable dessert shop. Unbuzzd is a single, unique, scientifically-backed recipe. The process described here is not just selling the dessert; it's building a massive, nationwide restaurant chain (the distribution platform) that knows exactly how to scale that unique recipe and market it to a trend-savvy, health-conscious customer base (the 70% of Americans seeking benefits). The appointment of the new CEO is like hiring a master architect to build the optimal store plan.

🧩 Final Takeaway 💡

Unbuzzd is leveraging strong clinical proof and a highly valuable market opportunity ($198B) to scale its proprietary product through a massive, multi-channel national rollout. The company is transforming from a niche supplement provider into a major contender in the functional beverage space under new leadership.